BioRestorative Therapies, Inc

Contributing Author

Recent Articles by BioRestorative Therapies, Inc

Apr-21	BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform BRTX -7.82% GlobeNewswire
Apr-07	BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform BRTX GlobeNewswire
Mar-30	BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease BRTX -10.94% GlobeNewswire
Mar-19	BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease BRTX +11.93% GlobeNewswire
Mar-05	BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026 BRTX GlobeNewswire
Mar-04	BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy BRTX GlobeNewswire
Feb-24	BioRestorative Expands Global Protection for ThermoStem, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs BRTX +37.01% GlobeNewswire
Feb-13	BioRestorative Announces Closing of $5.0 Million Public Offering BRTX GlobeNewswire
Feb-11	BioRestorative Announces Pricing of $5.0 Million Public Offering BRTX -40.50% GlobeNewswire
Feb-11	BioRestorative Announces Positive Outcome from Type B Meeting with FDA BRTX -35.41% GlobeNewswire
Feb-10	BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease BRTX -38.87% GlobeNewswire
Nov-17	BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease BRTX -6.77% GlobeNewswire
Nov-12	BioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update BRTX -9.42% BRTX GlobeNewswire
Nov-05	BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025 BRTX GlobeNewswire
Oct-27	BioRestorative Awarded Notice of Allowance for Japanese Patent - Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market BRTX GlobeNewswire
Oct-22	BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio BRTX GlobeNewswire
Oct-15	BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit BRTX GlobeNewswire
Oct-07	BioRestorative CEO Lance Alstodt Interviewed on "The Big Biz Show" BRTX +5.88% GlobeNewswire
Oct-06	BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market BRTX GlobeNewswire
Aug-12	BioRestorative Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update BRTX GlobeNewswire
Aug-05	BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025 BRTX GlobeNewswire
Jun-18	BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates BRTX GlobeNewswire
Jun-17	BioRestorative Announces Share Repurchase Program BRTX +6.17% GlobeNewswire
Jun-13	BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 - an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease BRTX -16.00% GlobeNewswire
Jun-10	BioRestorative Welcomes Serial Regenerative Medicine Entrepreneur, Company Builder and Leader, Sandy Lipkins, to BRTX Team BRTX GlobeNewswire
Jun-09	BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025 BRTX GlobeNewswire
May-14	BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update BRTX GlobeNewswire
May-13	Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data BRTX -7.09% GlobeNewswire
May-08	BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025 BRTX GlobeNewswire
May-07	BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025 BRTX GlobeNewswire

BioRestorative Therapies, Inc

Recent Articles by BioRestorative Therapies, Inc

Upgrade your Finviz experience